|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 47/48 | |
| A61K 38/26 | |||
| C07K 14/605 | |||
| A61P 3/10 |
| (11) | Patento numeris | 2073834 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 07842306.8 |
| Europos patento paraiškos padavimo data | 2007-09-12 | |
| (97) | Europos patento paraiškos paskelbimo data | 2009-07-01 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2013-10-23 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2007/078226 |
| Data | 2007-09-12 |
| (87) | Numeris | WO 2008/033888 |
| Data | 2008-03-20 |
| (30) | Numeris | Data | Šalis |
| 825472 P | 2006-09-13 | US | |
| 868391 P | 2006-12-04 | US |
| (72) |
BUSH, Mark, A., US
MATTHEWS, Jessica, E., US
WALKER, Susan, E., US
|
| (73) |
GlaxoSmithKline LLC,
One Franklin Plaza 200 North 16th Street, Philadelphia, PA 19102,
US
|
| (54) | USE OF LONG-LASTING FORMULATIONS OF GLP-1 PEPTIDES AS HYPOGLYCEMIC AGENTS |
| USE OF LONG-LASTING FORMULATIONS OF GLP-1 PEPTIDES AS HYPOGLYCEMIC AGENTS |